The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO

Topadur Pharma AG today announces the appointments of PD Dr. Matthias Schäfer and Prof. Dr. Jay Siegel.

Topadur Pharma AG and Oshen Holdings SA Partner to Develop a Treatment for Alopecia

CHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers

Topadur Pharma AG and Juvic Inc. Launch Transnational Collaboration for the Disease Management of Systemic Sclerosis

TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juvic Inc.

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.

TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.